Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Editas Medicine Stock Sank Today

TheMotleyFool

0 0

Shares of Editas Medicine (NASDAQ: EDIT) sank 11.4% as of the market close on Wednesday. The big decline came after AbbVie (NYSE: ABBV) announced a partnership with privately held Caribou Biosciences to develop chimeric antigen receptor T cell (CAR-T) therapies.

Why did AbbVie's deal with Caribou cause Editas stock to fall? Probably because the big drugmaker canceled a collaboration with Editas last year to develop a gene-editing therapy. Some investors appear to be viewing AbbVie's new partnership with Caribou as a clear snub of Editas.

Image source: Getty Images.

Source Fool.com

Like: 0

EDIT

Share